Dallas, Texas--(Newsfile Corp. - February 12, 2026) - Burcon Nutrascience Corporation (TSX: BU): Stonegate Capital Partners updates their coverage on Burcon Nutrascience Corporation (TSX: BU). Burcon's Galesburg production facility represents a pivotal transition from development-stage operations to commercial scale, with 3Q26 revenue of $739,000 reflecting approximately 107% quarter-over-quarter growth driven by protein sales and production activity at the site. Notably, the Company entered CY2025 without a production facility and exited the year meeting its revenue target, underscoring the speed of commercialization following Galesburg's launch. Management indicated that staffing and infrastructure are now in place, positioning incremental volume growth to occur with limited additional fixed costs and supporting operating leverage as throughput increases. Importantly, once a customer's product is commercialized, ingredient purchases typically recur on a month-to-month basis; with approximately 65-70% of expected growth tied to customers already purchasing and over 200 active projects in the pipeline, Galesburg serves as the backbone of durable, recurring revenue expansion.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Revenue increased 1,100% y/y
- Over 200 active projects
- Double digit revenue expected in CY26
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283706
